Clinical trials · Washington, D.C., DC
Adenocarcinoma clinical trials in Washington, D.C.
We’re tracking 108 recruiting adenocarcinoma studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT05080673Recruiting
Colonoscopy planning for small, noncancerous colon polyps
This trial tests whether people with 1–2 small, noncancerous colon polyps should get their next colonoscopy after 5 years or after 10 years. It may help reduce unnecessary procedures or find cancers earlier if the shorter interval is safer for you.
Washington D.C., District of ColumbiaAges 45–70 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05673148RecruitingPhase 3
Ablation treatment plus usual therapy for limited metastatic bowel cancer
This study tests whether adding “total ablation” (carefully destroying all visible small tumors using surgery, heat/cold treatment, and/or targeted radiation) to standard chemotherapy improves outcomes for people with limited spread of colorectal cancer. It may help by aiming to eliminate all known metastatic spots while you continue usual cancer treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Washington D.C., District of ColumbiaAges 40–75 - NCT06989437RecruitingPhase 2/Phase 3
Study of Ponsegromab for Pancreatic Cancer with Weight Loss
This study tests an experimental drug called ponsegromab for people with advanced pancreatic cancer who experience severe weight loss and fatigue. It aims to see if the drug can help improve weight and energy levels while you continue standard chemotherapy.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Arlington, VirginiaAges 18 years+ - NCT05548296RecruitingPhase 2
ACR-368 for high-grade endometrial cancer after prior treatments
This Phase 2 trial studies ACR-368 for people with high-grade endometrial cancer that has spread or grown despite at least one prior treatment. It may help by testing whether this drug can better control the cancer after other therapies have not worked.
Silver Spring, MarylandAges 18 years+ - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Silver Spring, MarylandAges 18 years+ - NCT06580314RecruitingPhase 3
Olaparib with or without bevacizumab for ovarian cancer
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Bethesda, MarylandAges 18 years+ - NCT06161532RecruitingPhase 2
Sacituzumab govitecan with or without atezolizumab for rare GU cancers
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Bethesda, MarylandAges 18–120 - NCT05616650RecruitingPhase 2
Targeted radiation for one prostate tumor spot
This Phase 2 study tests a focused radiation approach using stereotactic body radiation therapy (SBRT) for people with one prostate tumor visible on imaging. It aims to treat a single tumor area while limiting treatment to the rest of the prostate.
Bethesda, MarylandAges 18–120 - NCT06257693RecruitingPhase 1
Prostate cancer implant trial before prostate removal surgery
This trial tests a new enzalutamide implant (Enolen) placed in the prostate before surgery to see if it helps treat early prostate cancer. It is for men who are already planning to have their prostate removed.
Bethesda, MarylandAges 21 years+ - NCT00102544Enrolling by invitation
Tracking Devices to Find Abnormalities During Medical Procedures
This study tests technology that uses imaging scans to help doctors locate and reach abnormalities during surgical or interventional procedures. The goal is to make these image-guided procedures more accurate and safer for patients.
Bethesda, MarylandAges 18–120 - NCT06503146RecruitingPhase 2
New imaging tracer for detecting various cancers
This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.
Bethesda, MarylandAges 18–120 - NCT06041503RecruitingPhase 2
Treating rare bladder and testicular cancers with targeted therapy
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) for people with certain rare cancers of the urinary tract or testicles. The goal is to see if these treatments can shrink tumors or stop them from growing.
Bethesda, MarylandAges 18–120 - NCT02133196RecruitingPhase 2
T-cell treatment for lung cancer that has spread
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Bethesda, MarylandAges 18–72 - NCT00923026Enrolling by invitation
Follow-up for adults previously treated in NCI surgery studies
This study asks people age 18+ who were previously treated on certain NCI Surgery Branch (NCI-SB) studies to come back for follow-up. It helps researchers understand how patients do over time after those earlier treatments, including some gene therapy studies.
Bethesda, MarylandAges 18 years+ - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT05686226RecruitingPhase 2
Trial tests immune cells targeting HPV-16 cancers
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Bethesda, MarylandAges 18 years+
Hear when a new Adenocarcinoma trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Adenocarcinoma trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting adenocarcinoma studies listed above.
- National Institutes of Health Clinical Center · 11 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 5 studies
- George Washington University Hospital · 4 studies
- Georgetown University Medical Center · 3 studies
- MedStar Georgetown University Hospital · 3 studies
- Johns Hopkins University · 2 studies
- MedStar Washington Hospital Center · 2 studies
- NEXT Oncology · 2 studies
What taking part in a adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there adenocarcinoma clinical trials near Washington, D.C.?
- Yes. We're currently tracking 108 recruiting adenocarcinoma studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a adenocarcinoma study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New adenocarcinoma studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.